Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566618 · ClinicalTrials.gov registry record · Phase 1
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00566618: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00566618 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566618, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone. The safety and effectiveness of this combination will also be studied.
Interventions
- DRUG Dasatinib
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-11-01 |
| Est. Completion | 2020-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00566618
The ClinicalTrials.gov registry entry for NCT00566618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT00566618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00566618 about?
NCT00566618 is a clinical study titled "Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis". The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone. The safety and effectiveness of this combination will also be studied.
What is the current status of trial NCT00566618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-11-01. Estimated completion is 2020-11-17.
What interventions are being tested in trial NCT00566618?
The interventions under investigation include: Dasatinib (DRUG), Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00566618?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.